A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

NCT00967785 | Recruiting Phase 1

• 2 other identifiers: 09020009-I-0200
• Study Type: interventional
• Target: 20
• Locations: 1 country
• Sites: 1

Brief Summary

Background:

• WHIMS (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis Syndrome) is caused by various genetic changes that increase the activity of the chemokine receptor, CXCR4. Excessive function of this receptor causes mature neutrophils (part of the white blood cells) to be retained within the bone marrow rather than being released to the blood and is one of the causes of severe inherited neutropenia (low white blood counts). In neutropenia, the body is less able to fight off infection. Patients with WHIMS usually are at risk for skin, soft tissue, sinus, and lung infections, which can result in loss of hearing, teeth, and lung function.
• Current treatment for WHIMS consists of regular injections of a white blood cell growth stimulating medication called granulocyte colony stimulating factor (G-CSF), and supplemental immunoglobulin (antibody). These therapies are expensive, nonspecific, have significant side effects and toxicities, and do not fully correct all problems, especially warts and cancers related to human papillomavirus (HPV).
• A drug called Mozobil has been approved for use in combination with G-CSF to increase the number of stem cells that can be collected prior to bone marrow transplantation. Mozobil may offer a specific and well-tolerated new treatment for WHIMS and other syndromes characterized by neutropenia. Objectives:
• To evaluate whether Mozobil is safe and effective to treat neutropenia (low white blood cell count) in patients with WHIMS.
• To determine an appropriate treatment dose of Mozobil, within currently approved dosage levels. Eligibility: \- Individuals between 18 and 75 years of age who have been diagnosed with WHIMS and have a history of severe infections. Design:
• Potential participants will undergo a screening with a medical history, physical examination, questionnaire, heart and lung function scans, and blood and urine samples. Tests will also be done for hepatitis B and C virus, and human immunodeficiency virus (HIV) that causes acquired immunodeficiency syndrome (AIDS), as well as to check neutrophil function.
• Patients who are being treated with G-CSF will stop injections for 2 days before being admitted to the National Institutes of Health (NIH) Clinical Center.
• Patients may participate in a Dose Escalation study and receive increasing doses of Mozobil over 5 days of treatment until their white blood cell count improves sufficiently or the maximum approved dose is reached. Blood samples will be taken regularly throughout the treatment process. Patients will then receive an additional dose of Mozobil at the maximum approved dose or the dose sufficient to cause improvement, before restarting the G-CSF injections.
• Patients may also participate in a long-term Chronic Dosing study and receive Mozobil once or twice a day for up to a maximum of 60 months.

Conditions

Leukopenia; Neutropenia; Infections; Warts; Myelokathexis

Keywords

Neutropenia; Hypogammaglobulinemia; Myelokathexis; Warts; Immunodeficiency

Outcome Measures

Primary Outcomes (2)

• Safety

  No incident of grade 3/4 toxicities.

  Duration of treatment, up to 7 years

• Increase ANC

  Average ANC \> 250 and \> twice baseline level.

  Duration of treatment, up to 7 years.

Secondary Outcomes (2)

• reduced HPV lesions

  duration of treatnebt, up to 6 years.

• Increase Leucocytes

  prior to and after study drug

Study Arms (1)

Treatment Arm

ACTIVE COMPARATOR

neutropenia and infections

Drug: Mozobil (TM)

Interventions

Mozobil (TM) DRUG

twice daily subcutaneous injection or via continuous subcutaneous infusion

Treatment Arm

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Clinical diagnosis of WHIMS and documented severe infection
• Must be greater than or equal to 18 and less than or equal to 75 years of age
• Willingness to interrupt medications to raise the white count (WBC) such as G-CSF or GM-CSF for at least 2 days before and while on the study drug
• Must not be pregnant or breastfeeding
• Must have a personal physician
• Must be willing to provide blood, plasma, serum, and DNA samples for storage
• Subjects must agree not to become pregnant or to impregnate a female. If of childbearing potential, must agree to consistently use two types of contraception throughout study participation. Acceptable forms of contraception include the following:
• Condoms, male or female, with or without a spermicide
• Diaphragm or cervical cap with spermicide
• Intrauterine device
• Contraceptive pills or patch, Norplant, Depo-Provera or other FDA-approved contraceptive method
• Male partner has previously undergone a vasectomy for which there is documentation of aspermatogenic sterility

You may not qualify if:

• Absence of a diagnosis of WHIMS
• Patient is less than 18 years old
• Absence of a documented history of severe infection
• Neutropenia due to maturation defects in the myeloid lineage or that the PI feels is unlikely to benefit from this medication
• Pregnant women or breastfeeding
• History of serious cardiac arrhythmia or cardiac defects that make such more likely
• Renal failure (calculated creatinine clearance \[CrCl\] \<15 mL/min or requiring dialysis)
• Signs or symptoms of active microbial infection at the time of study entry.
• Any condition that, in the investigator s opinion, places the patient at undue risk by participating in the study
• Unwillingness to undergo testing or procedures associated with this protocol

Sponsors & Collaborators

• National Institute of Allergy and Infectious Diseases (NIAID): lead

Study Sites (1)

National Institutes of Health Clinical Center

Bethesda, Maryland, 20892, United States

RECRUITING

Related Publications (4)

• McDermott DH, Majumdar S, Velez D, Cho E, Li Z, Gao JL, Grieco MC, Lawrence MG, Silva SL, Castelo-Soccio LA, Follmann D, Murphy PM. Continuous Infusion of the CXCR4 Antagonist Plerixafor for WHIM Syndrome. medRxiv [Preprint]. 2025 Apr 22:2025.04.19.25325865. doi: 10.1101/2025.04.19.25325865.

  PMID: 40330596 DERIVED

• Broxmeyer HE. A WHIM satisfactorily addressed. Blood. 2014 Apr 10;123(15):2286-8. doi: 10.1182/blood-2014-02-557579.

  PMID: 24723677 DERIVED

• McDermott DH, Liu Q, Velez D, Lopez L, Anaya-O'Brien S, Ulrick J, Kwatemaa N, Starling J, Fleisher TA, Priel DA, Merideth MA, Giuntoli RL, Evbuomwan MO, Littel P, Marquesen MM, Hilligoss D, DeCastro R, Grimes GJ, Hwang ST, Pittaluga S, Calvo KR, Stratton P, Cowen EW, Kuhns DB, Malech HL, Murphy PM. A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor. Blood. 2014 Apr 10;123(15):2308-16. doi: 10.1182/blood-2013-09-527226. Epub 2014 Feb 12.

  PMID: 24523241 DERIVED

• McDermott DH, Liu Q, Ulrick J, Kwatemaa N, Anaya-O'Brien S, Penzak SR, Filho JO, Priel DA, Kelly C, Garofalo M, Littel P, Marquesen MM, Hilligoss D, Decastro R, Fleisher TA, Kuhns DB, Malech HL, Murphy PM. The CXCR4 antagonist plerixafor corrects panleukopenia in patients with WHIM syndrome. Blood. 2011 Nov 3;118(18):4957-62. doi: 10.1182/blood-2011-07-368084. Epub 2011 Sep 2.

  PMID: 21890643 DERIVED

Related Links

• NIH Clinical Center Detailed Web Page

MeSH Terms

Conditions

Leukopenia; Neutropenia; Infections; Warts; Agammaglobulinemia; Immunologic Deficiency Syndromes

Interventions

plerixafor

Condition Hierarchy (Ancestors)

Cytopenia; Hematologic Diseases; Hemic and Lymphatic Diseases; Leukocyte Disorders; Agranulocytosis; Papillomavirus Infections; DNA Virus Infections; Virus Diseases; Skin Diseases, Viral; Tumor Virus Infections; Skin Diseases, Infectious; Skin Diseases; Skin and Connective Tissue Diseases; Blood Protein Disorders; Lymphoproliferative Disorders; Lymphatic Diseases; Immune System Diseases

Study Officials

• David H McDermott, M.D.

  National Institute of Allergy and Infectious Diseases (NIAID)

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Elena J Cho

CONTACT

(301) 761-7280; elena.cho@nih.gov

David H McDermott, M.D.

CONTACT

(301) 761-6647; dmcdermott@niaid.nih.gov

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: NIH
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 27, 2009
• First Posted: August 28, 2009
• Study Start: January 6, 2010
• Primary Completion (Estimated): December 31, 2026
• Study Completion (Estimated): December 31, 2026
• Last Updated: April 8, 2026

Record last verified: 2025-08-11

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)